Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

9 May 2017

Abstract excerpt

Dear Editor, Blockade of PD-1/PD-L1 signaling pathway by monoclonal antibodies (MAbs) to release the anti-tumor activity of pre-existing tumor specific T cell immunity has initiated a new era for tumor immunotherapy. Administration of anti-PD-1 MAbs (nivolumab and pembrolizumab) in either monotherapy or in combination with anti-CTLA-4 MAbs or traditional chemotherapy has achieved a tumor regression rate of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28488247
DOI: 10.1007/s13238-017-0412-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumabPMID 28488247Read ↗

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Next generation of anti-PD-L1 Atezolizumab with better anti-tumor efficacy <i>in vivo</i>Semantic proximity Read ↗

Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007Semantic proximity Read ↗

PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.Semantic proximity Read ↗

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancerSemantic proximity Read ↗

Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.Semantic proximity Read ↗

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Human and mouse PD-L1: similar molecular structure, but different druggability profilesSemantic proximity Read ↗

Biological impediments to monoclonal antibody–based cancer immunotherapySemantic proximity Read ↗

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patientsSemantic proximity Read ↗

Shared Antigenic Epitopes and Pathobiological Functions of Anti-p185 Monoclonal AntibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.